Matsumoto K, Abe T, Terada K, Tabuchi A, Adachi Y, Mizumatsu S, Ono Y, Tamiya T, Ohmoto T, Furuta T
Department of Neurological Surgery, Okayama University Medical School, Japan.
No Shinkei Geka. 1999 Feb;27(2):139-45.
At present, there is no consensus concerning the treatment of low-grade gliomas. The authors conducted a retrospective review of surgically treated, histologically verified cases of supratentorial astrocytomas of grade II to evaluate the results of current treatment methods. Thirty-seven patients, 23 males and 14 females, treated from April, 1977 through March, 1997 were analyzed. Median patient age was 36 years (range 2-69 years). All patients were diagnosed by surgical specimens. Thirty were fibrillary, and three were gemistocytic astrocytomas. There were 13 total resections, 7 subtotal resections, 10 partial resections. Of the remaining 7, diagnosis was obtained by stereotactic biopsy. Twenty patients were irradiated and two received chemotherapy. Follow-up information was obtained for 33 patients. The follow-up time ranged from 4 months to 246 months (mean, 9 years). Overall survival rates at 5 and 10 years for the entire treated group were 71% and 57% respectively. Total and subtotal resections were significantly associated with longer survival time, the 5- and 10-year survival rates were 93% and 67%, respectively. They were 40% and 40% in patients with partial resection or needle biopsy. Patients with gemistocytic astrocytoma had a poor prognosis with a median survival of 44.5 months. The influence of radiotherapy was not obvious: 92 and 69% of patients were alive at 5 and 10 years respectively without radiotherapy. The extent of surgery and histological type were by far the most important factors in predicting length of survival. The importance of an accurate histologic diagnosis and a gross total resection is emphasized.
目前,关于低级别胶质瘤的治疗尚无共识。作者对经手术治疗、组织学确诊的幕上II级星形细胞瘤病例进行了回顾性研究,以评估当前治疗方法的效果。分析了1977年4月至1997年3月期间接受治疗的37例患者,其中男性23例,女性14例。患者中位年龄为36岁(范围2 - 69岁)。所有患者均通过手术标本确诊。30例为纤维型,3例为肥胖细胞型星形细胞瘤。全切除13例,次全切除7例,部分切除10例。其余7例通过立体定向活检确诊。20例患者接受了放疗,2例接受了化疗。获得了33例患者的随访信息。随访时间为4个月至246个月(平均9年)。整个治疗组5年和10年的总生存率分别为71%和57%。全切除和次全切除与较长的生存时间显著相关,5年和10年生存率分别为93%和67%。部分切除或穿刺活检患者的5年和10年生存率均为40%。肥胖细胞型星形细胞瘤患者预后较差,中位生存期为44.5个月。放疗的影响不明显:未接受放疗的患者5年和10年生存率分别为92%和69%。手术范围和组织学类型是预测生存时间最重要的因素。强调了准确的组织学诊断和大体全切的重要性。